TY  - JOUR
A1  - Krug, David
A1  - Hecht, Markus
A1  - Ebert, Nadja
A1  - Mäurer, Matthias
A1  - Fleischmann, Daniel F.
A1  - Fokas, Emmanouil
A1  - Straube, Christoph
A1  - Nicolay, Nils
A1  - Hörner-Rieber, Juliane
A1  - Schmitt, Daniela
A1  - Neubeck, Cläre von
A1  - Zamboglou, Constantinos
A1  - Sperk, Elena
A1  - Kaul, David
A1  - Heß, Julia
A1  - Corradini, Stefanie
A1  - Seidel, Clemens
A1  - Gani, Cihan
A1  - Baues, Christian Manfred
A1  - Frey, Benjamin
A1  - Blanck, Oliver
A1  - Gauer, Tobias
A1  - Niyazi, Karim-Maximilian
T1  - Innovative radiation oncology together – precise, personalized, human : vision 2030 for radiotherapy & radiation oncology in Germany
T2  - Strahlentherapie und Onkologie
N2  - Purpose: Scientific and clinical achievements in radiation, medical, and surgical oncology are changing the landscape of interdisciplinary oncology. The German Society for Radiation Oncology (DEGRO) working group of young clinicians and scientists (yDEGRO) and the DEGRO representation of associate and full professors (AKRO) are aware of the essential role of radiation oncology in multidisciplinary treatment approaches. Together, yDEGRO and AKRO endorsed developing a German radiotherapy & radiation oncology vision 2030 to address future challenges in patient care, research, and education. The vision 2030 aims to identify priorities and goals for the next decade in the field of radiation oncology. Methods: The vision development comprised three phases. During the first phase, areas of interest, objectives, and the process of vision development were defined jointly by the yDEGRO, AKRO, and the DEGRO board. In the second phase, a one-day strategy retreat was held to develop AKRO and yDEGRO representatives’ final vision from medicine, biology, and physics. The third phase was dedicated to vision interpretation and program development by yDEGRO representatives. Results: The strategy retreat’s development process resulted in conception of the final vision “Innovative radiation oncology Together – Precise, Personalized, Human.” The first term “Innovative radiation oncology” comprises the promotion of preclinical research and clinical trials and highlights the development of a national committee for strategic development in radiation oncology research. The term “together” underpins collaborations within radiation oncology departments as well as with other partners in the clinical and scientific setting. “Precise” mainly covers technological precision in radiotherapy as well as targeted oncologic therapeutics. “Personalized” emphasizes biology-directed individualization of radiation treatment. Finally, “Human” underlines the patient-centered approach and points towards the need for individual longer-term career curricula for clinicians and researchers in the field. Conclusion: The vision 2030 balances the ambition of physical, technological, and biological innovation as well as a comprehensive, patient-centered, and collaborative approach towards radiotherapy & radiation oncology in Germany.
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63758
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-637586
SN  - 1439-099X
N1  - Open Access funding enabled and organized by Projekt DEAL.
N1  - A Correction to this article was published on 03 November 2021. 10.1007/s00066-021-01869-z
N1  - This article has been updated
VL  - 197
SP  - 1043
EP  - 1048
PB  - Springer Medizin
CY  - Berlin ; Heidelberg
ER  -